Sera Prognostics Inc (SERA) - Total Liabilities
Based on the latest financial reports, Sera Prognostics Inc (SERA) has total liabilities worth $25.92 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Sera Prognostics Inc to track the company's year-over-year net asset growth rate.
Sera Prognostics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Sera Prognostics Inc's total liabilities have evolved over time, based on quarterly financial data. See Sera Prognostics Inc (SERA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Sera Prognostics Inc Competitors by Total Liabilities
The table below lists competitors of Sera Prognostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lloyds Engineering Works Limited
NSE:LLOYDSENGG
|
India | Rs6.86 Billion |
|
Quality Construction Products Public Company Limited
BK:Q-CON
|
Thailand | ฿397.47 Million |
|
Unitronics
TA:UNIT
|
Israel | ILA58.52 Million |
|
Global Data Centre Group
AU:GDC
|
Australia | AU$27.86 Million |
|
IBU tec advanced materials AG
XETRA:IBU
|
Germany | €16.58 Million |
|
NOMAD Power Solutions, Inc.
NASDAQ:NMAD
|
USA | $1.69 Million |
|
Freeman Gold Corp
V:FMAN
|
Canada | CA$1.40 Million |
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
USA | $10.62 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Sera Prognostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SERA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sera Prognostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sera Prognostics Inc (2019–2025)
The table below shows the annual total liabilities of Sera Prognostics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.52 Million | +7.08% |
| 2024-12-31 | $24.77 Million | -2.02% |
| 2023-12-31 | $25.28 Million | +45.42% |
| 2022-12-31 | $17.39 Million | +105.39% |
| 2021-12-31 | $8.46 Million | -28.60% |
| 2020-12-31 | $11.86 Million | -3.63% |
| 2019-12-31 | $12.30 Million | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of… Read more